The OVAL Study: GOG-3018 (VB-111-701) VB-111: A Randomized, Controlled, Double-Arm, Open-Label, Multip-Center + Paclitaxel v Paclitaxel Monotherapy in Recurrent Platinum-Resistant Ovarian Cancer

HUMAN CLINICAL STUDY - CONFIDENTIAL To examine the safety and tolerability of the combination of intravenous administration of VB-111 and paclitaxel compared to placebo and paclitaxel in patients with platinum resistant ovarian cancer. Patients enrolled in the study will be evaluated clinically and with standard laboratory tests before, at regular intervals during treatment period and approximately 30 days after discontinuation of treatment. Pateints will be followed for survival until deceased for a maximum of 5 years after last does of VB-111/placebo. To evaluate the efficacy of the combination of intravenous administration of VB-111 and paclitaxel compared to placebo and paclitaxel in patients with platinum resistanct ovarian cancer as measured by Overall SUrvival (OS) and by Progression Free Survival (PFS) by RECIST 1.1.